A new NEJM analysis provides clinicians with three essential takeaways regarding race-based medication dosing that have direct implications for patient care. First, racial categories poorly reflect the actual biological differences in drug metabolism that drive pharmacokinetic variation. Second, genetic testing and biomarker analysis offer significantly more precise alternatives for guiding treatment decisions. Third, continued reliance on racial categories in dosing protocols may inadvertently perpetuate health disparities rather than advance equitable care.
For practicing physicians, these findings suggest an opportunity to enhance clinical practice by transitioning toward precision medicine approaches. Rather than applying categorical assumptions, clinicians can now access pharmacogenetic testing that identifies individual drug-metabolizing capacity, enabling truly personalized dosing strategies.
This paradigm shift requires updating clinical guidelines, provider education, and healthcare infrastructure to support accessible genetic testing. The potential benefit—more effective treatment with reduced adverse outcomes—justifies the transition to evidence-based, individualized dosing approaches.
Read the full article on GMJ Newsroom.
Was this article helpful?
